Full Text
PCN57 TRASTUZUMAB USE FOR METASTATIC BREAST CANCER–IS “MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?

Abstract

Authors

A Hammerman SH Klang N Liebermann

Back to Volume 9, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×